Research progress in the benefit of sodium-glucose co-transporter 2 inhibitors in the treatment of heart failure / 中国医师杂志
Journal of Chinese Physician
;
(12): 149-152, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-932036
ABSTRACT
Heart failure is one of the two major problems in cardiovascular field in this century. Although the treatment of heart failure has made great progress, but the prognosis of heart failure is poor, Standardized drug treatment is still one of the most important and preferred methods for the treatment of heart failure. Heart failure is one of the serious vascular complications of diabetes, which affects the prognosis of diabetes. In recent years, studies have found that the new hypoglycemic drug sodium-glucose co-transporter 2 inhibitors can effectively reduce the risk of re-hospitalization and cardiovascular death in patients with or without diabetes, which has a landmark significance for the treatment of heart failure. This article will mainly discuss the latest mechanism of sodium glucose co-transporter 2 inhibitors in the treatment of heart failure.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Chinese Physician
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS